サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ウイルス・非ウイルスベクター製造市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年、ベクタータイプ別、適応症別、用途別、企業別、地域別セグメント
市場調査レポート
商品コード
1289659

ウイルス・非ウイルスベクター製造市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年、ベクタータイプ別、適応症別、用途別、企業別、地域別セグメント

Viral & Non-Viral Vector Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Vector Type, By Indication, By Application, By Company and By Region
出版日: | 発行: TechSci Research | ページ情報: 英文 116 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

ウイルス・非ウイルスベクター製造市場- 世界の産業規模、シェア、動向、機会、予測、2017-2027年、ベクタータイプ別、適応症別、用途別、企業別、地域別セグメント
出版日: 2023年06月01日
発行: TechSci Research
ページ情報: 英文 116 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のウイルス・非ウイルスベクター製造市場は、予測期間である2023-2027年に目覚ましい成長を遂げると予測されています。

主な要因としては、致命的な疾患の有病率の上昇、遺伝子および細胞治療製品の注目度の高まり、技術の広範な開拓などが挙げられ、これらは市場の成長を後押ししています。ベクターは遺伝子導入のためのツールであり、核細胞に遺伝物質を送り込むものです。ベクターには、ウイルス性ベクターと非ウイルス性ベクターの2種類があります。ウイルス性ベクターは、FDAが承認した遺伝子治療で一般的に使用されている送達手段ですが、非ウイルス性ベクターは、その安全性と有効性についてまだ研究されています。市場の成長を支えるその他の要因としては、広範な研究開発、患者数の増加、臨床研究の増加、公的機関だけでなく民間企業によるさまざまな投資、ベクターベースの遺伝子・細胞治療の普及、企業間の共同研究の増加、カスタマイズされた医薬品への需要の高さが挙げられます。

致命的な疾病の増加

糖尿病、ダウン症、インフルエンザ、肝臓がん、アルツハイマー病、心血管疾患などの遺伝性疾患、がん、感染症が世界的に増加していることが、市場の成長を後押ししています。WHOによると、心血管疾患（CVD）は世界の主要な死因であり、毎年約1790万人の命を奪っています。WHOによると、がんは主要な死因であり、2020年にはほぼ1000万人、つまり6人に1人の割合で死亡すると報告されています。これらの致命的な病気に苦しむ患者の増加により、治療用のベクターの需要が高まっています。例えば、2019年、FDAは天然痘とサル痘の両方を予防するために、Jynneosという市場名でMVA（Modified Vaccinia virus Ankara）を承認しました。

遺伝子治療・細胞治療製品の注目度の高まり

遺伝子治療とは、遺伝子の力を借りて病気の治療や予防を行う方法です。ベクターを用いた先進的な遺伝子・細胞治療法は、生物医学の分野に多大な影響を及ぼしています。様々な調査の結果、ベクターは特定の病気の予防や治療に使われるだけでなく、ベクターが持つ遺伝子情報を使って、病気の原因を直接狙ったり、細胞の機能を変化させたりできることがわかりました。また、ベクターを用いた遺伝子・細胞治療の普及率が高まっていることも、市場成長の一因となっています。そのため、数多くのイノベーター企業が、細胞・遺伝子治療用のウイルスベクターや非ウイルスベクターの開発・生産に積極的に取り組んでいます。例えば、2022年には、ジョンソン・エンド・ジョンソンが開発したCARVYKTI（TM）と名付けられた2番目のCAR-T療法がUSFDAによって承認され、再発または難治性の多発性骨髄腫の治療に使用されています。

利用可能なカスタマイズ

TechSci Researchは、与えられた市場データをもとに、企業の特定のニーズに応じてカスタマイズを提供します。本レポートでは、以下のカスタマイズが可能です：

企業情報

  • 追加市場プレイヤー（最大5社）の詳細な分析とプロファイリング

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のウイルス・非ウイルスベクター製造市場に与える影響

第5章 顧客の声

第6章 ウイルス・非ウイルスベクター製造の世界市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • ベクタータイプ別（ウイルスベクター、非ウイルスベクター）
    • 適応症別（がん、遺伝子疾患、感染症、心血管系疾患、その他）
    • 用途別（遺伝子治療、ワクチン療法、細胞治療、その他）
    • 地域別
    • 企業別（2021年）
  • 市場マップ

第7章 北米のウイルス・非ウイルスベクター製造市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • ベクタータイプ別（ウイルスベクターvs非ウイルスベクター）
    • 適応症別（がん、遺伝子疾患、感染症、心血管系疾患、その他）
    • 用途別（遺伝子治療、ワクチン療法、細胞治療、その他）
    • 国別
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第8章 欧州のウイルス・非ウイルスベクター製造市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • ベクタータイプ別（ウイルスベクターvs非ウイルスベクター）
    • 適応症別（がん、遺伝子疾患、感染症、心血管系疾患、その他）
    • 用途別（遺伝子治療、ワクチン療法、細胞治療、その他）
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第9章 アジア太平洋地域のウイルス・非ウイルスベクター製造市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • ベクタータイプ別（ウイルスベクター／非ウイルスベクター）
    • 適応症別（がん、遺伝子疾患、感染症、心血管系疾患、その他）
    • 用途別（遺伝子治療、ワクチン療法、細胞治療、その他）
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第10章 南米のウイルス・非ウイルスベクター製造市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • ベクタータイプ別（ウイルスベクター／非ウイルスベクター）
    • 適応症別（がん、遺伝子疾患、感染症、心血管系疾患、その他）
    • 用途別（遺伝子治療、ワクチン療法、細胞治療、その他）
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第11章 中東・アフリカのウイルス・非ウイルスベクター製造市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • ベクタータイプ別（ウイルスベクター／非ウイルスベクター）
    • 適応症別（がん、遺伝子疾患、感染症、心血管系疾患、その他）
    • 用途別（遺伝子治療、ワクチン療法、細胞治療、その他）
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • UAE

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場動向市場の動向と開拓

第14章 競合情勢

  • Catalent, Inc.
  • FUJIFILM Holdings Corporation
  • Danaher Corporation
  • Genscript Biotech Corporation
  • Lonza Group AG
  • Merck KGaA Inc.
  • Oxford Biomedica plc
  • Sartorius AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc

第15章 戦略的推奨事項

目次
Product Code: 13100

The global viral & non-viral vector manufacturing market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include the rising prevalence of fatal diseases, the growing prominence of gene and cell therapy products, and extensive development in technology, which are propelling the growth of the market. Vectors are tools for gene delivery, which deliver genetic material into the nucleic cell. They are of two types, viral and non-viral vectors. Viral vectors are commonly used delivery vehicles in FDA-approved gene therapies, whereas non-viral are still studied for their safety and efficacy. The other factors supporting the market's growth are the extensive research and development, an increasing number of patients, an increasing number of clinical studies, various investments by private as well public sectors, increasing prevalence of vector-based gene and cell treatments, the growing number of collaborations between companies, and the high demand for customized medications.

Rising Prevalence of Fatal Diseases

The increasing occurrence of genetic disorders, cancers, and infectious diseases, such as diabetes, down syndrome, flu, liver cancer, Alzheimer's disease, cardiovascular diseases, and others, across the globe are bolstering the growth of the market. According to the WHO, Cardiovascular diseases (CVDs) are the leading cause of death worldwide, taking approximately 17.9 million lives each year. As per WHO, cancer is a leading cause of death, reporting almost 10 million deaths, or nearly one in six deaths in 2020. Owing to the increasing number of patients suffering from these fatal diseases, the demand for vectors for treatment is rising. For instance, in 2019, the FDA approved MVA (Modified Vaccinia virus Ankara), under the market name Jynneos, to prevent both smallpox and monkeypox.

Growing Prominence of Gene and Cell Therapy Products

Gene therapy is a method to treat or prevent disease with the help of genetic material. Advanced gene and cell therapies, with the use of vectors, have considerably impacted the field of biomedicine. After various research, it is found that the vectors are not only used to prevent or treat specific diseases, but with the genetic information they have, they can directly target the cause of the disease and can alter the way a cell functions. The rising prevalence of vector-based gene and cell treatments is also a contributing factor to the growth of the market. Therefore, numerous innovator companies are actively involved in the development and production of viral vectors and non-viral vectors for cell and gene therapies. For instance, in 2022, the USFDA approved the second CAR-T therapy named CARVYKTI™, developed by Johnson and Johnson, which is used for the treatment of relapsed or refractory multiple myeloma.

Market Segmentation

The global viral & non-viral vector manufacturing market is segmented into vector type, indication, application, and company. Based on vector type, the market is segmented into viral vector and non-viral vector. Based on viral vector, the market is further segmented into adenoviral vector, retroviral vector, lentiviral vector, vaccinia viral vector, and others. Based on non-viral vector, the market is further segmented into plasmid DNA, lipid-based non-viral vector, polymer-based non-viral vector, and others. Based on indication, the market is divided into cancer, genetic disease, infectious disease, cardiovascular diseases, and others. Based on application, the market is divided into gene therapy, vaccinology, cell therapy, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising prevalence of genetic disorders, infectious diseases, chronic diseases, and cancers in the country.

Market Players

Catalent, Inc., FUJIFILM Holdings Corporation, Danaher Corporation, Genscript Biotech Corporation, Lonza Group AG, Merck KGaA Inc., Oxford Biomedica plc, Sartorius AG, Takara Bio Inc., and Thermo Fisher Scientific Inc are some of the leading companies operating in the market.

Report Scope

In this report, global viral & non-viral vector manufacturing market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Viral & Non-Viral Vector Manufacturing Market, By Vector Type:

  • Viral Vector
    • Adenoviral Vector
    • Retroviral Vector
    • Lentiviral Vector
    • Vaccinia Viral Vector
    • Others
  • Non-Viral Vector
    • Plasmid DNA
    • Lipid-Based Non-Viral Vector
    • Polymer-Based Non-Viral Vector
    • Others

Viral & Non-Viral Vector Manufacturing Market, By Indication:

  • Cancer
  • Genetic Disease
  • Infectious Disease
  • Cardiovascular Diseases
  • Others

Viral & Non-Viral Vector Manufacturing Market, By Application:

  • Gene Therapy
  • Vaccinology
  • Cell Therapy
  • Others

Viral & Non-Viral Vector Manufacturing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Viral & Non-Viral Vector Manufacturing Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Viral & Non-Viral Vector Manufacturing Market

5. Voice of Customer

6. Global Viral & Non-Viral Vector Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 6.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 6.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 6.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 6.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2021)
  • 6.3. Market Map

7. North America Viral & Non-Viral Vector Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 7.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 7.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 7.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 7.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Viral & Non-Viral Vector Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vector Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Application
    • 7.3.2. Mexico Viral & Non-Viral Vector Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vector Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Application
    • 7.3.3. Canada Viral & Non-Viral Vector Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vector Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Application

8. Europe Viral & Non-Viral Vector Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 8.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 8.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 8.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 8.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vector Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Application
    • 8.3.2. Germany Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vector Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Application
    • 8.3.3. United Kingdom Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vector Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Application
    • 8.3.4. Italy Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vector Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Application
    • 8.3.5. Spain Viral & Non-Viral Vector Manufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vector Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Application

9. Asia-Pacific Viral & Non-Viral Vector Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 9.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 9.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 9.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 9.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vector Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Application
    • 9.3.2. India Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vector Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Application
    • 9.3.3. Japan Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vector Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Application
    • 9.3.4. South Korea Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Vector Type
        • 9.3.4.2.2. By Indication
        • 9.3.4.2.3. By Application
    • 9.3.5. Australia Viral & Non-Viral Vector Manufacturing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Vector Type
        • 9.3.5.2.2. By Indication
        • 9.3.5.2.3. By Application

10. South America Viral & Non-Viral Vector Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 10.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 10.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 10.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 10.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Viral & Non-Viral Vector Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vector Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Application
    • 10.3.2. Argentina Viral & Non-Viral Vector Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vector Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Application
    • 10.3.3. Colombia Viral & Non-Viral Vector Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vector Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Application

11. Middle East and Africa Viral & Non-Viral Vector Manufacturing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Vector Type (Viral Vector v/s Non-Viral Vector)
      • 11.2.1.1. By Viral Vector (Adenoviral Vector, Retroviral Vector, Lentiviral Vector, Vaccinia Viral Vector, Others)
      • 11.2.1.2. By Non-Viral Vector (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Others)
    • 11.2.2. By Indication (Cancer, Genetic Disease, Infectious Disease, Cardiovascular Diseases, Others)
    • 11.2.3. By Application (Gene Therapy, Vaccinology, Cell Therapy, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Viral & Non-Viral Vector Manufacturing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Vector Type
        • 11.3.1.2.2. By Indication
        • 11.3.1.2.3. By Application
    • 11.3.2. Saudi Arabia Viral & Non-Viral Vector Manufacturing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Vector Type
        • 11.3.2.2.2. By Indication
        • 11.3.2.2.3. By Application
    • 11.3.3. UAE Viral & Non-Viral Vector Manufacturing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Vector Type
        • 11.3.3.2.2. By Indication
        • 11.3.3.2.3. By Application

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Catalent, Inc.
  • 14.2. FUJIFILM Holdings Corporation
  • 14.3. Danaher Corporation
  • 14.4. Genscript Biotech Corporation
  • 14.5. Lonza Group AG
  • 14.6. Merck KGaA Inc.
  • 14.7. Oxford Biomedica plc
  • 14.8. Sartorius AG
  • 14.9. Takara Bio Inc.
  • 14.10. Thermo Fisher Scientific Inc

15. Strategic Recommendations